LobbyingHighmark lobbying by quarter
Highmark's latest lobbying report covers Q2 2026, at $230K. The four quarters Q4 2025–Q3 2026 total $650K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.
Highmark
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $650K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $270K | 1 |
| Q1 2023 | $240K | 1 |
| Q2 2023 | $250K | 1 |
| Q3 2023 | $250K | 1 |
| Q4 2023 | $240K | 1 |
| Q1 2024 | $150K | 1 |
| Q2 2024 | $170K | 1 |
| Q3 2024 | $130K | 1 |
| Q4 2024 | $140K | 1 |
| Q1 2025 | $220K | 1 |
| Q2 2025 | $210K | 1 |
| Q3 2025 | $190K | 1 |
| Q4 2025 | $170K | 1 |
| Q1 2026 | $250K | 1 |
| Q2 2026 | $230K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$764K · 15 reports
- Medicare and Medicaid$764K · 15 reports
- Pharmacy$764K · 15 reports
- Taxation$764K · 15 reports
- Government issues$54K · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES15 reports
- SENATE15 reports
- Centers For Medicare and Medicaid Services (CMS)4 reports
- Health & Human Services, Dept of (HHS)2 reports
- White House Office2 reports
- Centers For Disease Control & Prevention (CDC)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseHighmark | $3.1M | 15 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | In-house | $230K |
| 07/17for Q3 | Kountoupes Denham Carr & Reid | Under $5,000 |
| 04/20for Q1 | In-house | $250K |
| 01/31for Q3 2025 | In-house | $190K |
| 01/31for Q4 2025 | In-house | $170K |
| 01/20for Q4 2025 | In-house | $150K |
| 25/10/17for Q3 2025 | In-house | $150K |
| 25/07/18for Q2 2025 | In-house | $210K |
| 25/04/18for Q1 2025 | In-house | $220K |
| 25/01/15for Q4 2024 | In-house | $140K |
| 24/10/17for Q3 2024 | In-house | $130K |
| 24/07/18for Q2 2024 | In-house | $170K |
| 24/04/19for Q1 2024 | In-house | $150K |
| 24/01/19for Q4 2023 | In-house | $240K |
| 23/10/20for Q3 2023 | In-house | $250K |
| 23/07/20for Q2 2023 | In-house | $250K |
| 23/04/20for Q1 2023 | In-house | $240K |
| 23/01/20for Q4 2022 | In-house | $270K |